AC Immune SA is a Swiss-based, clinical-stage biopharmaceutical company at the forefront of developing precision medicines for a wide range of neurodegenerative diseases. Leveraging its two proprietary technology platforms, SupraAntigen® (for biologics) and Morphomer® (for small molecules), AC Immune designs and develops innovative therapies targeting misfolded proteins, such as Abeta, Tau, and alpha-synuclein, which are hallmarks of conditions like Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders characterized by neuroinflammation. The company's pipeline includes diagnostic agents and therapeutic candidates, aiming to intervene early and effectively in disease progression. AC Immune is committed to advancing the understanding and treatment of these complex conditions through cutting-edge science and strategic collaborations.
The Lausanne headquarters serves as the central nexus for AC Immune's global operations, including cutting-edge research and development (R&D), corporate strategy, clinical trial management, and administrative functions.
Being part of the EPFL (Swiss Federal Institute of Technology Lausanne) Innovation Park provides AC Immune with access to state-of-the-art infrastructure, a rich talent pool, and a collaborative ecosystem of leading research institutions and technology companies. The facilities are modern and designed to support advanced scientific research.
AC Immune fosters a highly innovative, science-driven work culture. Employees often describe it as collaborative and dynamic, with a strong emphasis on scientific excellence and a shared mission to combat neurodegenerative diseases. The environment encourages critical thinking and problem-solving.
The location in Lausanne, within the EPFL Innovation Park, is significant due to its proximity to world-class academic research, a strong local biotech cluster, and Switzerland's stable and supportive environment for life sciences companies. This enhances AC Immune's R&D capabilities and global partnerships.
While headquartered in Switzerland, AC Immune has a significant global presence driven by its clinical development programs and collaborations. The company conducts multinational clinical trials for its therapeutic candidates across North America, Europe, and other key regions, partnering with leading research institutions and clinical research organizations (CROs). Its strategic alliances with pharmaceutical companies also extend its reach, facilitating the development and potential commercialization of its innovative treatments for neurodegenerative diseases worldwide.
EPFL Innovation Park, Building B
Lausanne
Vaud
Switzerland
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AC Immune' leadership includes:
AC Immune has been backed by several prominent investors over the years, including:
In the past 12 months, AC Immune strengthened its financial leadership with the appointment of a new Chief Financial Officer, marking a key transition in its executive team.
Discover the tools AC Immune uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AC Immune likely employs standard corporate email formats for its employees. While specific internal structures may vary, a common professional format is 'firstname.lastname@acimmune.com'. Variations such as 'firstinitiallastname@acimmune.com' could also be in use.
first.last@acimmune.com
Format
andrea.pfeifer@acimmune.com
Example
80%
Success rate
GlobeNewswire • May 15, 2024
AC Immune announced its Q1 2024 financial results, highlighting progress in its Alzheimer's and Parkinson's disease programs, including updates on ACI-24.060 and ACI-7104.056, and its solid cash position to fund operations....more
GlobeNewswire • April 25, 2024
AC Immune confirmed the dosing of the first patient in its ReTain Phase 2b clinical trial evaluating ACI-24.060, an anti-amyloid beta vaccine candidate, for individuals with early Alzheimer's disease....more
GlobeNewswire • March 7, 2024
The company reported its full-year 2023 financial results, outlining strategic priorities, clinical pipeline advancements, and anticipated milestones for its neurodegenerative disease programs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AC Immune, are just a search away.